LINEZOLID INJECTION 2 MG — DIN 02430827
LINEZOLID : 2 MG · FRESENIUS KABI CANADA LTD · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is LINEZOLID INJECTION?
LINEZOLID INJECTION 2 MG contains LINEZOLID : 2 MG. It is listed in the Health Canada Drug Product Database under DIN 02430827, held by FRESENIUS KABI CANADA LTD, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 12-Jun-2015. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is LINEZOLID INJECTION used for?
Adults: Vancomycin-Resistant Enterococcus faecium (VREF); Nosocomial pneumonia; Community-acquired pneumonia; Complicated skin and skin structure infections (including diabetic foot infections).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Linezolid cost around the world?
Linezolid is listed on 15 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max); Czechia publishes a max producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| South Africa | single exit price | 23 | 25 | ZAR███.██ |
| Saudi Arabia | public | 14 | 16 | SAR███.██ |
| Austria | KVP (Kassenverkaufspreis) | 7 | 15 | EUR███.██ |
| United States | acquisition | 2 | 15 | USD███.██ |
| Czechia | max producer price (ex-factory) | 6 | 12 | CZK███.██ |
| Romania | max producer price | 9 | 12 | RON███.██ |
| Greece | producer price (ex-factory) | 11 | 11 | EUR███.██ |
| Bahrain | retail (max) | 6 | 10 | BHD███.██ |
| United Arab Emirates | public | 9 | 9 | AED███.██ |
| Norway | max AUP (pharmacy retail) | 4 | 8 | NOK███.██ |
| Sweden | AIP (pharmacy purchase price) | 7 | 7 | SEK███.██ |
| Italy | prezzo al pubblico (classe A) | 3 | 5 | EUR███.██ |
| Italy | ex-factory (classe H) | 3 | 5 | EUR███.██ |
| Slovakia | categorised final price | 4 | 4 | EUR███.██ |
| United Kingdom | hospital | 2 | 2 | GBP███.██ |
| Luxembourg | reimbursement | 2 | 2 | EUR███.██ |
158 pack listings across 112 brand entries and 15 price bases, refreshed 07 Sep 2026. Ranges span every Linezolid pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Linezolid in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
13 holders have a Canadian DIN containing Linezolid, across 19 DINs, of which 8 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| PFIZER CANADA ULC | 3 | 2 | ZYVOXAM, ZYVOXAM 600 MG | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 2 | 2 | JAMP LINEZOLID, LINEZOLID INJECTION | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 2 | 1 | LINEZOLID INJECTION, SANDOZ LINEZOLID | Sourceable in Canada |
| APOTEX INC | 1 | 1 | APO-LINEZOLID | Sourceable in Canada |
| EUGIA PHARMA INC. | 1 | 1 | LINEZOLID INJECTION | Sourceable in Canada |
| FRESENIUS KABI CANADA LTD | 1 | 1 | LINEZOLID INJECTION | Sourceable in Canada |
| MDA INC. | 2 | 0 | LINEZOLID INJECTION, LINEZOLID INTRAVENOUS INJECTION | No marketed DIN |
| TEVA CANADA LIMITED | 2 | 0 | LINEZOLID INJECTION, NOVO-LINEZOLID | No marketed DIN |
| HOSPIRA HEALTHCARE ULC | 1 | 0 | LINEZOLID INJECTION | No marketed DIN |
| PANDA PHARMACEUTICALS INC. | 1 | 0 | LINEZOLID | No marketed DIN |
| PHARMARIS CANADA INC | 1 | 0 | LINEZOLID INJECTION | No marketed DIN |
| STRIDES PHARMA CANADA INC | 1 | 0 | LINEZOLID TABLETS | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 2 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | Single-use, ready-to-use flexible plastic infusion bags (PVC-free, DEHP-free) in a foil laminate overwrap. 600 mg linezolid in 300 mL of solution per bag. |
| Storage | Supplied as a ready-to-use sterile isotonic solution. (Specific temperature range not explicitly stated in provided text, but noted as ready-to-use). |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Linezolid |
|---|---|
| ATC code | J01XX08 |
| AHFS class | 08:12.28.24 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02430827 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2430827 |
| Brand name | LINEZOLID INJECTION |
| Generic / active ingredient | LINEZOLID : 2 MG |
| Market authorization holder | FRESENIUS KABI CANADA LTD |
| Health Canada schedule | Prescription |
| ATC code | J01XX08 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J01XX |
| Current status | MARKETED |
| Status date | 12-Jun-2015 |
| Original market date | 2015-06-12 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
600 mg intravenous every 12 hours (q12h). Infusion over 30 to 120 minutes. Duration typically 10 to 28 days depending on infection type.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to linezolid; use of MAO inhibitors within 2 weeks; uncontrolled hypertension, pheochromocytoma, thyrotoxicosis, carcinoid syndrome unless monitored for BP/serotonin syndrome.
Warnings and precautions
Myelosuppression (monitor CBC weekly); Lactic acidosis; Serotonin syndrome; Peripheral/optic neuropathy (long-term use); CDAD; Hyponatremia; Rhabdomyolysis. Not for Gram-negative infections.
Is Linezolid in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by FRESENIUS KABI CANADA LTD, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
8 of 19 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-LINEZOLID | 600 MG | TABLET | APOTEX INC | MARKETED | 02426552 |
| JAMP LINEZOLID | 600 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02520354 |
| LINEZOLID INJECTION | 2 MG | SOLUTION | EUGIA PHARMA INC. | MARKETED | 02539748 |
| LINEZOLID INJECTION | 2 MG | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | 02481278 |
| SANDOZ LINEZOLID | 600 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | 02422689 |
| ZYVOXAM | 100 MG / 5 ML | POWDER FOR SUSPENSION | PFIZER CANADA ULC | MARKETED | 02243686 |
| ZYVOXAM | 2 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | 02243685 |
| LINEZOLID | 600 MG | TABLET | PANDA PHARMACEUTICALS INC. | CANCELLED PRE MARKET | 02457903 |
| LINEZOLID INJECTION | 2 MG | SOLUTION | SANDOZ CANADA INCORPORATED | CANCELLED PRE MARKET | 02429527 |
| LINEZOLID INJECTION | 2 MG | SOLUTION | TEVA CANADA LIMITED | CANCELLED POST MARKET | 02402637 |
2 · Same class — other molecules in ATC J01XX
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Linezolid | APO-LINEZOLID · JAMP LINEZOLID · LINEZOLID · LINEZOLID INJECTION · +6 more | 19 | 8 | Yes |
| Daptomycin | CUBICIN · CUBICIN RF · DAPTOMYCIN FOR INJECTION · DAPTOMYCIN FOR INJECTION RF | 13 | 3 | Yes |
| Fosfomycin | FOSFOMYCIN POWDER FOR ORAL SOLUTION · IVOZFO · JAMP-FOSFOMYCIN · MONUROL | 6 | 3 | Yes |
| Bacitracin | BACIJECT · BACITRACIN FOR INJECTION · BACITRACIN FOR INJECTION, USP · BACITRACIN USP | 5 | 1 | Yes |
| Lefamulin | XENLETA | 2 | 0 | Not in Canada |
| Methenamine | HIP REX TAB 1GM · MANDELAMINE | 2 | 0 | Not in Canada |
| Methenamine, Combinations | SAPROLEX TAB · URASAL GRANULES | 2 | 0 | Not in Canada |
| Tedizolid | SIVEXTRO | 2 | 0 | Not in Canada |
| Spectinomycin | TROBICIN INJ 400MG/ML | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J01X
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J01XA | Dalbavancin · Telavancin · Vancomycin | 62 | 23 |
| J01XE | Nitrofurantoin | 24 | 9 |
| J01XB | Colistin · Polymyxin B | 6 | 4 |
| J01XD | Metronidazole | 7 | 2 |
| J01XC | Fusidic Acid | 3 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is LINEZOLID INJECTION called?
The same molecule, Linezolid, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Linezolid Accord | Latin | Czechia, Norway, Sweden |
| Linezolid Krka | Latin | Czechia, Norway, Sweden |
| Zersa | Latin | Bahrain, Saudi Arabia |
| Linezolid Sandoz | Latin | Czechia, Norway, Sweden |
| Zenix | Latin | Bahrain, Saudi Arabia |
| Linezolid Fresenius Kabi | Latin | Norway |
| LINEZOLID OLIKLA | Latin | Czechia |
| Voxwin Tablets | Latin | South Africa |
| Zillion | Latin | Saudi Arabia |
| Zodinex | Latin | Bahrain, Saudi Arabia |
| ZYVOX | Latin | Bahrain |
| ZYVOXID | Latin | Czechia |
| Aklid | Latin | South Africa |
| ELTURIN IV | Latin | South Africa |
| KINZADO | Latin | Saudi Arabia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.